Exploiting T cell signaling to optimize engineered T cell therapies

doi:10.1016/j.trecan.2021.10.007

	Exploiting T cell signaling to optimize engineered T cell therapies
	Wang, Haopeng1,2 ; Song, Xianming 3; Shen, Lianjun 4; Wang, Xinxin 4; Xu, Chenqi 5,6
	2022-02
发表期刊	TRENDS IN CANCER (IF:14.3[JCR-2023],17.1[5-Year])
ISSN	2405-8025
EISSN	2405-8033
卷号	8 期号:2
发表状态	已发表
DOI	10.1016/j.trecan.2021.10.007
摘要	Engineered T cell therapies, mainly chimeric antigen receptor (CAR)-T and T cell receptor (TCR)-T, have become the new frontier of cancer treatment. CAR-T and TCR-T therapies differ in many aspects, including cell persistence and toxicity, leading to different therapeutic outcomes. Both TCR and CAR recognize antigens and trigger T cell mediated antitumor response, but they have distinct molecular structures and signaling properties. TCR represents one of the most complex receptors, while CAR is a single-chain chimera integrating modules from multiple immune receptors. Understanding the mechanisms underlying the strengths and limitations of both systems can pave the way for the development of next generation T cell therapy. This review synthesizes recent findings on TCR and CAR signaling and highlights the potential strategies of T cell engineering by signaling refinement.
URL	查看原文
收录类别	SCI ; SCIE
语种	英语
资助项目	National Natural Science Foundation of China (NSFC)[31861133009] ; Chinese Academy of Sciences (CAS) grants (Chinese Academy of Sciences Facility-based Open Research Program)["YSBR-014","QYZDB-SSW-SMC048"] ; National Key Research and Development Program of China[2019YFA0111000]
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000745031600006
出版者	CELL PRESS
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/153564
专题	生命科学与技术学院_PI研究组_王皞鹏组
通讯作者	Wang, Haopeng; Xu, Chenqi
作者单位	1.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China 2.Shanghai Clin Res & Trial Ctr, Shanghai, Peoples R China 3.Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China 4.Gracell Biotechnol, Shanghai, Peoples R China 5.Chinese Acad Sci, Univ Chinese Acad Sci, State Key Lab Mol Biol, Shanghai Inst Biochem & Cell Biol,Ctr Excellence, Shanghai, Peoples R China 6.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Life Sci, Hangzhou, Zhejiang, Peoples R China
第一作者单位	生命科学与技术学院
通讯作者单位	生命科学与技术学院
第一作者的第一单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Wang, Haopeng,Song, Xianming,Shen, Lianjun,et al. Exploiting T cell signaling to optimize engineered T cell therapies[J]. TRENDS IN CANCER,2022,8(2).
APA	Wang, Haopeng,Song, Xianming,Shen, Lianjun,Wang, Xinxin,&Xu, Chenqi.(2022).Exploiting T cell signaling to optimize engineered T cell therapies.TRENDS IN CANCER,8(2).
MLA	Wang, Haopeng,et al."Exploiting T cell signaling to optimize engineered T cell therapies".TRENDS IN CANCER 8.2(2022).